Mona Shahriari, MD, FAAD

In this episode, sisters and dermatologists Mona and Neda Shahriari discuss mentorship, motherhood, and the meaning of sisterhood in medicine.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

This episode highlights the challenges of navigating demanding medical careers while raising young children, with insights and practical strategies.

Laura Ferris, MD, PhD, reflects on her unexpected path to department chair as well as the lessons of her journey as a leader in academic medicine.

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry.

In this video, the last in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fifth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fourth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.

Melinda Gooderham, MD, MSc, joins The Medical Sisterhood to discuss balancing mentorship, leadership, and family, as well as the empowerment of women in the medical field.

In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.

Amy Spizuoco, DO, joins the show to discuss her journey as a key opinion leader in dermatology.

In this interview, Mona Shahriari, MD, and Raj Chovatiya, MD, PhD, touched on the evolving role of pharmacists and internal medicine doctors in atopic dermatitis.

In this interview, Chovatiya and Shahriari highlight notable elements of the upcoming Revolutionizing Atopic Dermatitis (RAD) Conference.

Jennifer Soung, MD, joins The Medical Sisterhood to discuss her journey to launching LEADderm and how owning the podium has changed her career.

Mona Shahriari, MD, previews the upcoming Revolutionizing Atopic Dermatitis Annual Meeting being held in Nashville, TN from June 06-07.

A pair of experts discuss unmet needs and educational gaps related to atopic dermatitis.

Panelists discuss how the future of atopic dermatitis treatments is evolving with novel biologics, Janus kinase inhibitors, and precision medicine targeting immune pathways. Advances in gene therapy, microbiome modulation, and personalized treatments offer promising long-term management options.

Panelists discuss how shared decision-making in atopic dermatitis care involves collaboration between health care providers and patients, considering individual preferences, values, and treatment goals. This approach enhances treatment adherence and improves outcomes through personalized, informed choices.

Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.

Panelists discuss how the JADE EXTEND study (Shi 2022) found that most patients who achieved EASI-75 with dupilumab also responded to abrocitinib. Even some dupilumab nonresponders achieved EASI-75. Adverse events (AEs) included nausea, acne, and headache.

Panelists discuss how the JADE COMPARE study (Bieber 2021) found similar EASI-75 response rates at 16 weeks for abrocitinib (71.0% at 200 mg, 60.3% at 100 mg) and dupilumab (65.5%). Abrocitinib had more nausea/acne; dupilumab had more conjunctivitis. Adverse effect (AE) withdrawal rates were low.

Panelists discuss how the Measure Up 1 and 2 studies (Simpson 2022) showed that at 52 weeks, 82.0% to 84.9% of upadacitinib patients achieved EASI-75. Common adverse effects (AEs) included acne, cough, and headache, with 4.5% to 7.2% withdrawal rates.

Panelists discuss how Janus kinase (JAK) inhibitors such as upadacitinib, abrocitinib, and baricitinib offer rapid, oral treatment for moderate to severe atopic dermatitis, differing from injectable biologics in administration, broader immunosuppression, and risk of adverse events like thromboembolism. They provide effective symptom control but require safety monitoring.

Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.

Panelists discuss how the 2-year ECZTEND study found tralokinumab effective for atopic dermatitis, with 82.5% achieving EASI-75 and 59.8%, EASI-90. Common adverse effects (AEs) included upper respiratory tract infections, dermatitis, headache, and conjunctivitis. The treatment-emergent adverse event (TEAE) withdrawal rate was 1.6%.

Panelists discuss how The LIBERTY AD OLE study (Beck 2024) showed sustained efficacy of treatment in atopic dermatitis, with 96.9% achieving EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90 over 260 weeks. Common adverse events (AEs) included nasopharyngitis, atopic dermatitis (AD) worsening, upper respiratory tract infections, herpes infections, and conjunctivitis. Treatment-emergent adverse event (TEAE)–related withdrawal was 3.8%.

Panelists discuss how common adverse effects impact treatment decisions, requiring adjustments. Experienced adverse reactions are managed with tailored interventions, monitoring, and patient education to ensure optimal care.